
Opdivo to be made available to UK melanoma patients via the Cancer Drugs Fund
pharmafile | November 30, 2018 | News story | Medical Communications, Sales and Marketing | BMS, Bristol-Myers Squibb, Cancer, Cancer Drugs Fund, NICE, UK, melanoma, pharma
Bristol-Myers Squibb’s blockbuster immunotherapy Opdivo (nivolumab) is set to be made available to patients in the UK via the Cancer Drugs Fund as a treatment option for melanoma, NICE has revealed, in a U-turn on a ruling made earlier this year.
Specifically, Opdivo will be reimbursed to patients with stage 3 and 4 melanoma who have lymph node involvement and who have previously undergone surgery – a group of eligible patients which NICE estimates numbers around 1,480.
The organisation also confirmed that the submitted findings suggested that there was potential for Opdivo to be a cost-effective use of resources for routine NHS use, but further clinical data would be needed on its efficacy in improving recurrence-free and overall survival. NICE did note that the data already indicates that Opdivo is superior to compared to BMS’ other immunotherapy Yervoy in the former of the two metrics.
The drug’s availability on the CDF will help allow these data to be procured, as well as follow-up findings from the ongoing CheckMate 238 trial. There are currently no immunotherapy products recommended by NICE in this indication.
The final appraisal document is open for appeal until 14 December 2018.
Matt Fellows
Related Content

Amphista doses first patient in AML trial of protein degrader
Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an …

NICE recommends daratumumab quadruplet for newly diagnosed multiple myeloma
NICE has published final draft guidance recommending daratumumab with bortezomib, lenalidomide and dexamethasone (D-VRd) for …

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …





